<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>7(7)</volume><submitter>Choschzick M</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>The aim of this study is to demonstrate the feasibility of automatic classification of Ki-67 histological immunostainings in patients with squamous cell carcinoma of the vulva using a deep convolutional neural network (dCNN).&lt;h4>Material and methods&lt;/h4>For evaluation of the dCNN, we used 55 well characterized squamous cell carcinomas of the vulva in a tissue microarray (TMA) format in this retrospective study. The tumor specimens were classified in 3 different categories C1 (0-2%), C2 (2-20%) and C3 (>20%), representing the relation of the number of KI-67 positive tumor cells to all cancer cells on the TMA spot. Representative areas of the spots were manually labeled by extracting images of 351 × 280 pixels. A dCNN with 13 convolutional layers was used for the evaluation. Two independent pathologists classified 45 labeled images in order to compare the dCNN's results to human readouts.&lt;h4>Results&lt;/h4>Using a small labeled dataset with 1020 images with equal distribution among classes, the dCNN reached an accuracy of 90.9% (93%) for the training (validation) data. Applying a larger dataset with additional 1017 labeled images resulted in an accuracy of 96.1% (91.4%) for the training (validation) dataset. For the human readout, there were no significant differences between the pathologists and the dCNN in Ki-67 classification results.&lt;h4>Conclusion&lt;/h4>The dCNN is capable of a standardized classification of Ki-67 staining in vulva carcinoma; therefore, it may be suitable for quality control and standardization in the assessment of tumor grading.</pubmed_abstract><journal>Heliyon</journal><pagination>e07577</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8346648</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Deep learning for the standardized classification of Ki-67 in vulva carcinoma: A feasibility study.</pubmed_title><pmcid>PMC8346648</pmcid><pubmed_authors>Ciritsis A</pubmed_authors><pubmed_authors>Gut A</pubmed_authors><pubmed_authors>Choschzick M</pubmed_authors><pubmed_authors>Rossi C</pubmed_authors><pubmed_authors>Boss A</pubmed_authors><pubmed_authors>Hejduk P</pubmed_authors><pubmed_authors>Alyahiaoui M</pubmed_authors></additional><is_claimable>false</is_claimable><name>Deep learning for the standardized classification of Ki-67 in vulva carcinoma: A feasibility study.</name><description>&lt;h4>Background&lt;/h4>The aim of this study is to demonstrate the feasibility of automatic classification of Ki-67 histological immunostainings in patients with squamous cell carcinoma of the vulva using a deep convolutional neural network (dCNN).&lt;h4>Material and methods&lt;/h4>For evaluation of the dCNN, we used 55 well characterized squamous cell carcinomas of the vulva in a tissue microarray (TMA) format in this retrospective study. The tumor specimens were classified in 3 different categories C1 (0-2%), C2 (2-20%) and C3 (>20%), representing the relation of the number of KI-67 positive tumor cells to all cancer cells on the TMA spot. Representative areas of the spots were manually labeled by extracting images of 351 × 280 pixels. A dCNN with 13 convolutional layers was used for the evaluation. Two independent pathologists classified 45 labeled images in order to compare the dCNN's results to human readouts.&lt;h4>Results&lt;/h4>Using a small labeled dataset with 1020 images with equal distribution among classes, the dCNN reached an accuracy of 90.9% (93%) for the training (validation) data. Applying a larger dataset with additional 1017 labeled images resulted in an accuracy of 96.1% (91.4%) for the training (validation) dataset. For the human readout, there were no significant differences between the pathologists and the dCNN in Ki-67 classification results.&lt;h4>Conclusion&lt;/h4>The dCNN is capable of a standardized classification of Ki-67 staining in vulva carcinoma; therefore, it may be suitable for quality control and standardization in the assessment of tumor grading.</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Jul</publication><modification>2024-02-15T11:30:57.463Z</modification><creation>2022-02-11T06:54:50.727Z</creation></dates><accession>S-EPMC8346648</accession><cross_references><pubmed>34386617</pubmed><doi>10.1016/j.heliyon.2021.e07577</doi></cross_references></HashMap>